scholarly journals High-risk patients benefit from lowering of LDL-cholesterol

Prescriber ◽  
2015 ◽  
Vol 26 (3) ◽  
pp. 30-31
Author(s):  
Susan Mayor
Keyword(s):  
High Risk ◽  
Ldl Cholesterol ◽  
High Risk Patients ◽  
Risk Patients

LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?

Drugs ◽  
2013 ◽  
Vol 73 (4) ◽  
pp. 293-301 ◽  
Author(s):  
Joost Besseling ◽  
Julian van Capelleveen ◽  
John J. P. Kastelein ◽  
G. Kees Hovingh
Keyword(s):  
High Risk ◽  
Ldl Cholesterol ◽  
High Risk Patients ◽  
Risk Patients ◽  
Low Do

Abstract 18396: Low Rate of LDL-Goal-Attainment in 57,855 High-Risk-Patients in Europe, Canada, South-Africa, Middle East and China - Results of DYSIS

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Anselm K Gitt ◽  
Dominik Lautsch ◽  
Martin Horack ◽  
Baishali Ambegaonkar ◽  
Jean Ferrieres ◽  
...  
Keyword(s):  
Clinical Practice ◽  
High Risk ◽  
Secondary Prevention ◽  
Goal Attainment ◽  
Ldl Cholesterol ◽  
Statin Treatment ◽  
Lipid Lowering ◽  
High Risk Patients ◽  
Risk Patients ◽  
Very High

Background: Statin treatment is routinely used for secondary prevention world-wide. Little is known about the prevalence of persistent lipid abnormalities under chronic statin treatment for secondary prevention and possible differences in LDL-Cholesterol (LDL-C) goal attainment in clinical practice between countries in different parts of the world. Methods: Between 2008 and 2012, consecutive statin-treated outpatients were enrolled in 26 countries worldwide, (DYSIS = Dyslipidemia International Study; list of countries in table) to assess LDL-C goal attainment for secondary prevention. European Society of Cardiology recommendations were used to classify patient risk, and to define LDL-cholesterol treatment goals. Data were collected under real life conditions in physicians’ offices and hospital outpatient wards. Results: Serum lipid values of 57,885 consecutive statin-treated outpatients were studied in the context of their cardiovascular risk factors, and the potency and composition of their lipid-lowering treatment. In the very-high risk patients only 21.7% did reach the currently recommended LDL-Chol target <70mg/dl with large differences between the countries varying from 9.2% to 44.3%. In the high-risk population the LDL-Chol target <100mg/dl was achieved in 38.0% oft he patients, varying between 16.6% and 66.7% between countries Conclusion: Despite chronic statin treatment, only 21.7% of the very-high-risk patients reached the current recommended LDL-Chol target <70mg/dl in this large multinational cross-sectional trial, highlighting the persistent large gap between guideline recommendations and clinical practice. Further treatment escalations are necessary to reduce the risk of subsequent cardiovascular events.

The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients

2011 ◽  
Vol 27 (10) ◽  
pp. 1961-1961
Author(s):  
Dimitri P. Mikhailidis ◽  
Richard W. Lawson ◽  
Anna-Louise McCormick ◽  
Gillian C. Sibbring ◽  
Andrew M. Tershakovec ◽  
...  
Keyword(s):  
High Risk ◽  
Goal Attainment ◽  
Ldl Cholesterol ◽  
High Risk Patients ◽  
Cholesterol Goal ◽  
Risk Patients ◽  
Very High

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab

2016 ◽  
Vol 12 (2) ◽  
pp. 149-157 ◽  
Author(s):  
Chanukya Dahagam ◽  
Aditya Goud ◽  
Abdelhai Abdelqader ◽  
Aditya Hendrani ◽  
Matthew J Feinstein ◽  
...  
Keyword(s):  
High Risk ◽  
Ldl Cholesterol ◽  
Pcsk9 Inhibitors ◽  
High Risk Patients ◽  
Cholesterol Levels ◽  
Risk Patients
Sign in / Sign up

Export Citation Format

Share Document